25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. / Kanstrup, Charlotte; Teilum, Dorthe; Rejnmark, Lars; Bigaard, Janne Villemoes; Eiken, Pia; Kroman, Niels; Tjønneland, Anne; Mejdahl, Mathias Kvist.

I: Breast Cancer Research and Treatment, Bind 179, Nr. 3, 2020, s. 699-708.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Kanstrup, C, Teilum, D, Rejnmark, L, Bigaard, JV, Eiken, P, Kroman, N, Tjønneland, A & Mejdahl, MK 2020, '25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival', Breast Cancer Research and Treatment, bind 179, nr. 3, s. 699-708. https://doi.org/10.1007/s10549-019-05486-4

APA

Kanstrup, C., Teilum, D., Rejnmark, L., Bigaard, J. V., Eiken, P., Kroman, N., Tjønneland, A., & Mejdahl, M. K. (2020). 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. Breast Cancer Research and Treatment, 179(3), 699-708. https://doi.org/10.1007/s10549-019-05486-4

CBE

Kanstrup C, Teilum D, Rejnmark L, Bigaard JV, Eiken P, Kroman N, Tjønneland A, Mejdahl MK. 2020. 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. Breast Cancer Research and Treatment. 179(3):699-708. https://doi.org/10.1007/s10549-019-05486-4

MLA

Kanstrup, Charlotte o.a.. "25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival". Breast Cancer Research and Treatment. 2020, 179(3). 699-708. https://doi.org/10.1007/s10549-019-05486-4

Vancouver

Kanstrup C, Teilum D, Rejnmark L, Bigaard JV, Eiken P, Kroman N o.a. 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. Breast Cancer Research and Treatment. 2020;179(3):699-708. https://doi.org/10.1007/s10549-019-05486-4

Author

Kanstrup, Charlotte ; Teilum, Dorthe ; Rejnmark, Lars ; Bigaard, Janne Villemoes ; Eiken, Pia ; Kroman, Niels ; Tjønneland, Anne ; Mejdahl, Mathias Kvist. / 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival. I: Breast Cancer Research and Treatment. 2020 ; Bind 179, Nr. 3. s. 699-708.

Bibtex

@article{5b7fca5445e04905804cf8ac4afa188b,
title = "25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival",
abstract = "PURPOSE: Previous studies have shown that low levels of 25-hydroxyvitamin D (25(OH)D) are associated with a poorer breast cancer survival. The relationship between vitamin D status and breast cancer outcomes is however still debated. The aim of the present study was to investigate the association between 25(OH)D blood levels measured at time of diagnosis and event-free survival (EFS) and overall survival (OS) in a large cohort of patients with early-stage primary invasive breast cancer.METHODS: From April 2008 to April 2013, 25(OH)D status was measured at time of diagnosis in all women operated for early stage primary invasive breast cancer at Rigshospitalet, Copenhagen, Denmark. Associations between 25(OH)D and EFS and OS were investigated using a Cox Proportional hazards model, adjusting for age, disease characteristics, time period, and BMI. Differences in survival were evaluated by hazard ratios (HR).RESULTS: In the present study, 2510 women with primary invasive breast cancer were included. Women with the lowest 25(OH)D levels (≤ 52 nmol/L) had an inferior EFS with a HR of 1.63 (95% CI 1.21-2.19) compared to women in the third quartile (76-99 nmol/L). Women with the highest 25(OH)D levels (≥ 99 nmol/L) also had an inferior EFS with a HR of 1.37 (95% CI 1.02-1.83). Plotting 25(OH)D status against EFS, the association was inversely J-shaped. For OS, a similar association with 25(OH)D status was observed.CONCLUSION: We confirmed previous findings suggesting that a low 25(OH)D status is associated with an inferior breast cancer survival, but unlike previous findings, we found an indication of poorer breast cancer survival also among women with high 25(OH)D levels.",
keywords = "25 Hydroxyvitamin D, Breast cancer, Prognosis, Survival, Vitamin D",
author = "Charlotte Kanstrup and Dorthe Teilum and Lars Rejnmark and Bigaard, {Janne Villemoes} and Pia Eiken and Niels Kroman and Anne Tj{\o}nneland and Mejdahl, {Mathias Kvist}",
year = "2020",
doi = "10.1007/s10549-019-05486-4",
language = "English",
volume = "179",
pages = "699--708",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

RIS

TY - JOUR

T1 - 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival

AU - Kanstrup, Charlotte

AU - Teilum, Dorthe

AU - Rejnmark, Lars

AU - Bigaard, Janne Villemoes

AU - Eiken, Pia

AU - Kroman, Niels

AU - Tjønneland, Anne

AU - Mejdahl, Mathias Kvist

PY - 2020

Y1 - 2020

N2 - PURPOSE: Previous studies have shown that low levels of 25-hydroxyvitamin D (25(OH)D) are associated with a poorer breast cancer survival. The relationship between vitamin D status and breast cancer outcomes is however still debated. The aim of the present study was to investigate the association between 25(OH)D blood levels measured at time of diagnosis and event-free survival (EFS) and overall survival (OS) in a large cohort of patients with early-stage primary invasive breast cancer.METHODS: From April 2008 to April 2013, 25(OH)D status was measured at time of diagnosis in all women operated for early stage primary invasive breast cancer at Rigshospitalet, Copenhagen, Denmark. Associations between 25(OH)D and EFS and OS were investigated using a Cox Proportional hazards model, adjusting for age, disease characteristics, time period, and BMI. Differences in survival were evaluated by hazard ratios (HR).RESULTS: In the present study, 2510 women with primary invasive breast cancer were included. Women with the lowest 25(OH)D levels (≤ 52 nmol/L) had an inferior EFS with a HR of 1.63 (95% CI 1.21-2.19) compared to women in the third quartile (76-99 nmol/L). Women with the highest 25(OH)D levels (≥ 99 nmol/L) also had an inferior EFS with a HR of 1.37 (95% CI 1.02-1.83). Plotting 25(OH)D status against EFS, the association was inversely J-shaped. For OS, a similar association with 25(OH)D status was observed.CONCLUSION: We confirmed previous findings suggesting that a low 25(OH)D status is associated with an inferior breast cancer survival, but unlike previous findings, we found an indication of poorer breast cancer survival also among women with high 25(OH)D levels.

AB - PURPOSE: Previous studies have shown that low levels of 25-hydroxyvitamin D (25(OH)D) are associated with a poorer breast cancer survival. The relationship between vitamin D status and breast cancer outcomes is however still debated. The aim of the present study was to investigate the association between 25(OH)D blood levels measured at time of diagnosis and event-free survival (EFS) and overall survival (OS) in a large cohort of patients with early-stage primary invasive breast cancer.METHODS: From April 2008 to April 2013, 25(OH)D status was measured at time of diagnosis in all women operated for early stage primary invasive breast cancer at Rigshospitalet, Copenhagen, Denmark. Associations between 25(OH)D and EFS and OS were investigated using a Cox Proportional hazards model, adjusting for age, disease characteristics, time period, and BMI. Differences in survival were evaluated by hazard ratios (HR).RESULTS: In the present study, 2510 women with primary invasive breast cancer were included. Women with the lowest 25(OH)D levels (≤ 52 nmol/L) had an inferior EFS with a HR of 1.63 (95% CI 1.21-2.19) compared to women in the third quartile (76-99 nmol/L). Women with the highest 25(OH)D levels (≥ 99 nmol/L) also had an inferior EFS with a HR of 1.37 (95% CI 1.02-1.83). Plotting 25(OH)D status against EFS, the association was inversely J-shaped. For OS, a similar association with 25(OH)D status was observed.CONCLUSION: We confirmed previous findings suggesting that a low 25(OH)D status is associated with an inferior breast cancer survival, but unlike previous findings, we found an indication of poorer breast cancer survival also among women with high 25(OH)D levels.

KW - 25 Hydroxyvitamin D

KW - Breast cancer

KW - Prognosis

KW - Survival

KW - Vitamin D

U2 - 10.1007/s10549-019-05486-4

DO - 10.1007/s10549-019-05486-4

M3 - Journal article

C2 - 31707511

VL - 179

SP - 699

EP - 708

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -